Exelixis (EXEL) vs Immunovant (IMVT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Immunovant (IMVT) has outperformed Exelixis (EXEL) over the past year, gaining 88.2% versus a gain of 52.7%. Over five years, IMVT leads with a +247.0% price change compared with +170.5% for EXEL. Exelixis is the larger company by market cap ($14.62 billion vs $6.25 billion), about 2.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EXEL | IMVT |
|---|---|---|
| Share price | $59.02 | $30.26 |
| Market cap | $14.62B | $6.25B |
| 1-day change | +0.99% | -5.56% |
| YTD return | +34.66% | +19.04% |
| 1-year return | +52.74% | +88.24% |
| 5-year return | +170.49% | +247.02% |
| P/E ratio (TTM) | 18.62 | — |
| Forward P/E | 13.92 | — |
| EPS (TTM) | $3.17 | $-2.82 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.32B | — |
| Revenue growth (YoY) | +6.98% | — |
| Net income (latest FY) | $782.57M | $-505.61M |
| Gross margin | 96.39% | — |
| Operating margin | 37.59% | — |
| Net margin | 33.73% | — |
| 52-week high | $61.14 | $45.42 |
| 52-week low | $33.76 | $16.08 |
| Distance from 52-week high | -3.47% | -33.38% |
| Analyst consensus | buy | buy |
| Avg. price target upside | -7.61% | +61.53% |
| Average volume | 2.34M | 1.22M |
| Shares outstanding | 247.78M | 206.55M |
| Employees | 1,077 | 315 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Exelixis is about 2.3 times larger than Immunovant by market value ($14.62B vs $6.25B).
- IMVT has outperformed EXEL by 35.5 percentage points over the past year.
About Exelixis
EXEL stock →Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,077 employees
About Immunovant
IMVT stock →Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 315 employees
EXEL vs IMVT FAQ
Which is bigger, Exelixis or Immunovant?
Exelixis (EXEL) is larger, with a market capitalization of $14.62B compared with $6.25B for Immunovant (IMVT).
Which stock has performed better over the past year, EXEL or IMVT?
IMVT returned +88.24% over the past 12 months, compared with +52.74% for EXEL (price return, excluding dividends). Past performance does not predict future results.
Are Exelixis and Immunovant in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.